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Original Contribution
Nitrated ﬁbrinogen is a biomarker of oxidative stress in
venous thromboembolism
Marissa Martinez, Adam Cuker, Angela Mills, Richard Lightfoot, Yiying Fan,
W.H. Wilson Tang, Stanley L. Hazen, Harry Ischiropoulos
Introduction
Venous thromboembolism (VTE) is a common thrombotic 
disease that encompasses both deep vein thrombosis (DVT) and 
pulmonary embolism (PE). VTE affects around 1 per 1000 people 
per year within the United States, with increasing incidence for 
congenital and acquired thrombophilic risk factors [1 3]. VTE is a 
chronic disease with 30% of patients experiencing a recurrent 
event over 10 years [4,5] and is estimated to account for between 
100,000 and 180,000 deaths each year [6]. Thus, VTE represents a 
signiﬁcant health problem that requires considerable attention.
The precise molecular and biochemical mechanisms of throm 
bus initiation in VTE remain unclear. Virchow proposed that 
changes in blood rheology, induction of a hypercoagulable 
state, or endothelial injury are conditions required for venous 
thrombosis [7]. More recent studies indicate that inﬂammation
plays an important role in VTE. However, the interplay between 
inﬂammation and Virchow’s triad is still unresolved. One possi 
bility is that components of the triad activate or damage 
endothelial cells within the vein wall resulting in upregulation 
of receptors for inﬂammatory and procoagulant molecules. Elec 
tron micrographs of early thrombus formation show leukocyte 
adhesion to the vein wall [8], presumably through the binding of 
P and E selectins that are expressed on activated endothelial 
cells [9,10]. Leukocytes shed tissue factor bearing microparticles, 
which induce coagulation and the production of a ﬁbrin clot [11]. 
Neutrophils and monocytes, two of the most prevalent leukocytes 
in venous thrombi, are also able to generate nitrating intermedi 
ates, capable of lipid peroxidation and nitration of proteins 
[12,13].
One protein known to be modiﬁed by tyrosine nitration is the 
coagulant protein ﬁbrinogen. Upon activation of the coagulation 
cascade, circulating plasma ﬁbrinogen is cleaved by thrombin to 
ﬁbrin monomers, which polymerize to form a ﬁbrin clot. Recent 
studies demonstrate an emerging role for nitrated ﬁbrinogen that 
links inﬂammation and oxidant production to coagulation.
Nitrated ﬁbrinogen is elevated in the plasma of patients with
coronary artery disease (CAD) and in smokers [14,15]. Addition
ally, in humans injected with small amounts of lipopolysacchar
ide, plasma levels of nitrated ﬁbrinogen increase and remain
elevated for at least 72 h postinjection [16]. This increase follows
an elevation of circulating myeloperoxidase, an enzyme localized
to the azurophilic granules of neutrophils, which is released
during neutrophil activation and is capable of generating nitrating
intermediates [12]. Although these data suggest that nitrated
ﬁbrinogen plays a key role linking inﬂammation, oxidant produc
tion, and arterial thrombotic diseases, its role in VTE remains
undeﬁned.
Moreover, nitrated ﬁbrinogen is not simply a marker of
inﬂammation and oxidative stress, but also has functional effects
on ﬁbrinogen and ﬁbrin clotting. Fibrinogen nitration was shown
to increase the rate of ﬁbrin clot formation, diminish clot lysis
rate, and alter ﬁbrin clot structural and viscoelastic properties
[14 16]. These functional effects suggest that nitrated ﬁbrinogen
may represent a risk factor for increased thrombotic tendency
during inﬂammation and oxidant stress. However, the levels of
nitrated ﬁbrinogen in VTE have not been ascertained. Herein we
quantiﬁed the levels of nitrated ﬁbrinogen in patients presenting
to the emergency department with suspected VTE and evaluated
if nitrated ﬁbrinogen is a biochemical risk factor that could
explain associations of oxidative stress and inﬂammation with
thrombotic complications in VTE.
Materials and methods
Patient population
We performed a prospective cohort study from January 2010
to March 2011 of consecutive subjects 18 years of age or older
presenting to the Hospital of the University of Pennsylvania
emergency department with suspected acute lower extremity
DVT or PE. Exclusion criteria included history of VTE within the
prior 4 weeks, unavailable for 90 day follow up, and inability to
provide informed consent. DVT was diagnosed by compression
ultrasonography and PE by computed tomographic pulmonary
angiography. Patients with negative imaging were contacted by
telephone 90 days after enrollment to conﬁrm that they did not
develop clinically apparent VTE. Those who reported develop
ment of VTE over this interval despite negative imaging were also
considered positive for DVT and/or PE. Secondary variables were
also collected, including demographic information, thrombotic
risk factors, comorbidities, and medications. Before initiation of
anticoagulant therapy in the emergency department, blood was
collected from patients in 3.2% sodium citrate (BD Vacutainer;
Franklin Lakes, NJ, USA). Blood was centrifuged at 150g for
15 min, and the supernatant, platelet rich plasma, was trans
ferred to a new tube. Platelet rich plasma was then centrifuged at
10,000g for 10 min to obtain platelet poor plasma, followed by
storage at 80 1C for future analysis. Study design was approved
by the Institutional Review Board Involving Human Subjects at
the University of Pennsylvania and written informed consent was
obtained from all study participants.
Plasma nitrated ﬁbrinogen levels
Nitrated ﬁbrinogen levels were measured in plasma using an
ELISA described previously [16]. Brieﬂy, 96 well plates were
coated with 10 mg/ml anti nitrotyrosine antibodies generated
and described elsewhere [17] in 50 mM carbonate buffer, pH 9,
and incubated at 4 1C under constant rocking overnight. The next
day, the plates were washed with 50 mM Tris, 150 mM NaCl,
0.05% Tween 20 (TBS T). The plates were blocked with 3% bovine
serum albumin (BSA; Roche Diagnostics, Mannheim, Germany)
(wt/vol) in TBS T for 2 h at 37 1C, followed by incubation with 1%
BSA in TBS T for 1 h at 37 1C. A standard curve was created from
puriﬁed ﬁbrinogen (American Diagnostica, Stamford, CT, USA)
that had been chemically nitrated and the levels of nitration were
independently determined [16]. Plasma samples were diluted
(1:10, 1:20) in 1% BSA in TBS T, added to the plate in duplicate,
and incubated 2 h at room temperature under constant rocking.
Plates were washed with TBS T and coated with 0.3 mg/ml horse
radish peroxidase (HRP) conjugated rabbit anti human ﬁbrinogen
polyclonal antibody (DakoCytomation, Glostrup, Denmark) in 1%
BSA in TBS T. After 2 h incubation at room temperature under
gentle rocking, the plates were washed with TBS T and developed
with TMB substrate (KPL, Gaithersburg, MD, USA) followed by
quenching of the reaction with 2 M sulfuric acid (Fisher Scientiﬁc,
Fair Lawn, NJ, USA). The absorbance was measured at 405 nm
(Molecular Devices, Sunnyvale, CA, USA). Nitrated ﬁbrinogen
values were normalized to quality control plasma run with each
plate. Each patient sample was analyzed a minimum of three
times and samples that exceeded 15% coefﬁcient of variation were
excluded from analysis. The normalized mean intra assay and
interassay variations were 8.23 and 9.32%.
Plasma ﬁbrinogen level
Fibrinogen levels were measured in plasma using an ELISA
previously described [16]. Ninety six well plates (Maxisorb;
Nunc, Rochester, NY, USA) were coated with 10 mg/ml mouse
anti ﬁbrinogen monoclonal antibody [16] in carbonate buffer,
pH 9, and incubated at 4 1C, rocking overnight. The next day,
the plates were washed with TBS T and blocked with 3% BSA in
TBS T for 2 h at 37 1C. A standard curve was created from puriﬁed
ﬁbrinogen (American Diagnostica) in TBS T. Plasma was diluted
(1:5000, 1:10,000), added to the plate in triplicate, and incubated
for 1 h at 37 1C. The plates were washed with TBS T, then coated
with 0.3 mg/ml HRP conjugated rabbit anti human ﬁbrinogen
polyclonal antibody (DakoCytomation) in 1% BSA in TBS T, and
incubated 1 h at room temperature. The plate was developed with
the TMB peroxidase substrate as described above. Fibrinogen
values were normalized to quality control plasma run with each
plate. The normalized mean intra assay and interassay variations
were 11.23 and 14.0%.
Plasma ﬁbrinogen levels were measured by the Clauss method
[18] using a Destiny Max coagulation analyzer according to the
manufacturer’s protocol (Trinity Biotech, County Wicklow,
Ireland).
D dimer
Plasma D dimer levels were measured at the University of
Pennsylvania Hospital Coagulation Laboratory using the Vidas
D dimer exclusion assay (bioMe´rieux, Lyon, France). This assay
measures the ﬁbrin degradation product (FDP) D dimer by an
enzyme linked ﬂuorescence assay. This sandwich ELISA based
method uses two anti FDP monoclonal antibodies (P10B5E12C9
and P2C5A10) coupled with ﬂuorescence detection [19,20]. In
accordance with the manufacturer’s instructions, a D dimer level
of o0.5 mg/ml was considered negative.
The laboratory personnel and technologists performing all
assays were blinded to patient outcome. Laboratory results
obtained on the archived plasma samples were not made avail
able to clinicians or patients.
Statistics
Gaussian distribution was tested for all continuous variables
using a D’Agostino and Pearson omnibus normality test, which
indicated nonparametric distributions for all variables within our
data. Thus, comparisons between groups were made using the
Mann Whitney U test. Nitrated ﬁbrinogen, D dimer, and ﬁbrinogen
are given as the mean and the 95% conﬁdence interval (CI). The
adjusted model for nitrated ﬁbrinogen levels was created using the
generalized linear model, which accounted for demographics, comor
bidities, and VTE risk factors. Odds ratios were compared by Fisher’s
exact test. Trends in nitrated ﬁbrinogen levels by quartile were
compared by w2 analysis. A P value o0.05 was considered statisti
cally signiﬁcant. All statistical calculations were generated and
analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA,
USA) or R Statistical package (http://www.r project.org/).
Results
Patient characteristics
A total of 251 patients were enrolled in this study. Of the 83
subjects with suspected DVT, 18 had a positive ultrasound and an
additional 3 were determined to be positive on 90 day follow up.
Among the 168 subjects with suspected PE, 28 had a positive
computed tomographic pulmonary angiography and 1 additional
patient was found to have new PE at 90 days. Patient demo
graphics, disease history, risk factors, and medications are shown
in Table 1. Three well accepted risk factors for VTE were more
prevalent in the VTE positive subset: advanced age, active cancer,
and surgery within the past 6 weeks. VTE positive patients were
signiﬁcantly older compared with negative patients and were
more likely to have active cancer or recent surgery. Thrombophi
lia testing was not performed as part of the study. Nevertheless,
3 patients reported a history of hereditary thrombophilia, includ
ing 1 with protein C and 2 with protein S deﬁciency. Additionally,
2 patients reported having antiphospholipid syndrome. No other
measured demographic variables, comorbidities, risk factors, or
medication use differed between VTE positive and VTE negative
patients (Table 1).
Fibrinogen levels in VTE patients
Fibrinogen levels were quantiﬁed by ELISA, which measures
ﬁbrinogen antigen, and the Clauss assay, which measures ﬁbrin
clotting time. The mean levels of ﬁbrinogen compared by Mann
Whitney U test were not different between subjects with and
without VTE by either Clauss assay or by ELISA (Fig. 1A). Fibrino
gen levels were also similar between DVT and PE patients
irrespective of the assay employed (Clauss: DVT, n¼17, 3.8 mg/ml,
95% CI 3.0 4.6; PE, n¼27, 4.5 mg/ml, 95% CI 3.6 5.4. ELISA: DVT,
n¼21, 5.5 mg/ml, 95% CI 4.4 6.5; PE, n¼28, 5.6 mg/ml, 95%
CI 4.7 6.5; Fig. 1A). ELISA determined ﬁbrinogen levels were
higher than those reported by Clauss assay, which is consistent
with ﬁndings in previous studies [21].
Nitrated ﬁbrinogen levels in VTE patients
Nitrated ﬁbrinogen was measured by an ELISA as described
previously [16]. The levels of nitrated ﬁbrinogen were interpo
lated from a standard curve created with puriﬁed ﬁbrinogen that
was chemically nitrated, and levels of nitration were indepen
dently determined [16]. To ensure the integrity of each assay,
every 96 well plate included a quality control plasma standard,
and intra and interassay variation did not exceed 15%. The mean
levels of nitrated ﬁbrinogen were signiﬁcantly higher in VTE
positive compared to VTE negative patients (Fig. 1B). Nitrated
ﬁbrinogen levels were not different between DVT and PE patients
(DVT, n¼17, 60.9 nM, 95% CI 52.3 69.6; PE, n¼27, 63.9 nM, 95%
CI 55.2 72.5).
Previous data indicated that one functional effect of ﬁbrinogen
tyrosine nitration was increased rate of ﬁbrin formation. Because
the Clauss assay relies on ﬁbrin clotting time in plasma to assess
ﬁbrinogen levels, Spearman correlation analysis was used to
evaluate the relationship between nitrated ﬁbrinogen and ﬁbri
nogen levels (Fig. 1C). Nitrated ﬁbrinogen correlated linearly with
Clauss measured ﬁbrinogen levels (n¼207, r¼0.31, 95% CI 0.18 0.40;
Po0.0001).
D dimer levels in VTE patients
D dimers are ﬁbrin degradation products that are produced in
response to clot lysis by plasmin and are used as a diagnostic
marker for VTE [19,22 25]. D dimer was measured with the Vidas
D dimer exclusion assay according to the manufacturer’s instruc
tions. As expected, mean D dimer levels were signiﬁcantly higher
in VTE positive versus VTE negative patients (Fig. 1D).
Odds ratio for venous thromboembolism across increasing nitrated
ﬁbrinogen levels
Cubic spline curves with 95% CI (n¼226) were constructed to
illustrate the relationship between nitrated ﬁbrinogen levels and
Table 1
Characteristics of VTE patient population.
Non-VTE (n 201) VTE (n 50) P value
Age (years) 47.6716.7 53.3716.4 0.0206a
Gender (% male) 63 (31.3%) 23 (46.0%)
BMI (kg/m2) 31.479.2 28.976.7
Race and ethnicity
Caucasian 75 (37.3%) 26 (52.0%)
African American 121 (60.2%) 22 (44.0%)
Other 5 (2.5%) 2 (4.0%)
Hispanic 6 (3.0%) 2 (4.0%)
Disease history and risk factors
H/O DVT 35 (17.4%) 9 (18.0%)
H/O PE 28 (13.9%) 7 (14.0%)
H/O CAD/MI/angina 15 (8.2%) 5 (6.8%)
H/O stroke 15 (7.5%) 4 (8.0%)
Liver disease 9 (4.5%) 2 (4.0%)
Lupus 8 (4.0%) 0 (0.0%)
Rheumatoid arthritis 4 (2.0%) 1 (2.0%)
Peripheral artery disease 5 (2.5%) 4 (8.0%)
Active cancer 38 (18.9%) 19 (38.0%) 0.0075b
Recent surgeryc 26 (12.9%) 15 (30.0%) 0.0089b
Immobilization 4 6 weeks 30 (14.9%) 11 (22.0%)
Air travelc 4 (2.0%) 2 (4.0%)
Tobacco use 77 (38.3%) 17 (34.0%)
Pregnancy 5 (2.5%) 4 (8.0%)
Trauma 11 (5.5%) 3 (6.0%)
Infection 19 (9.5%) 5 (10.0%)
Medication
Antiplatelet 32 (15.9%) 8 (16.0%)
Anticoagulant 25 (12.4%) 8 (16.0%)
Statins 36 (17.9%) 11 (22.0%)
Hormonal contraception 9 (4.5%) 4 (8.0%)
Hormone therapy 1 (0.5%) 1 (2.0%)
Antioxidants 6 (3.0%) 3 (6.0%)
Immunosuppressants 29 (14.4%) 4 (8.0%)
Values shown are means7SD or the number and percentage of the sample group.
VTE composition: DVT, n 21; PE, n 29.
a Age and BMI were compared by Mann–Whitney U test.
b All other variables were compared by Fischer’s exact test.
c Within past 6 weeks.
the odds ratio of clinically documented VTE (Fig. 2). This analysis
shows a strong association between nitrated ﬁbrinogen levels and
increased risk for VTE (Po0.005). A similar relationship was
found for rates of VTE across increasing nitrated ﬁbrinogen
quartiles (w2 for trend 7.69; Po0.01; Table 2). Patients in the
highest quartile were compared with those in the lowest quartile
and were found to have an increased risk of VTE (Table 2). This
risk was maintained after univariate adjustment for the risk
factors found to be elevated in our VTE positive patient popula
tion: advanced age, active cancer, and recent surgery (Table 2,
Models 1, 2, and 3). However, multivariate analysis with these
risk factors did not reach statistical signiﬁcance (Table 2, Model
4). This may reﬂect the small size of our VTE positive patient
population, in that additional adjustments reduce the ﬁnal sam
ple size and eliminate statistical signiﬁcance.
Discussion
Previous studies have implied that inﬂammation and oxidative
processes may be mechanistically linked to the pathogenesis of
VTE [12 16,26 31]. Nitration of proteins and, speciﬁcally,
nitrated ﬁbrinogen have been quantiﬁed in the plasma of subjects
who experience inﬂammatory changes and oxidative burden
[14 16]. In this study the data indicate that oxidants, speciﬁcally
nitrating intermediates produced in response to inﬂammation in
VTE, result in nitration of ﬁbrinogen. The levels of nitrated
ﬁbrinogen were signiﬁcantly elevated in patients with acute
VTE compared to those negative for the disease. This increase
was not dependent on changes in ﬁbrinogen, as mean levels of
ﬁbrinogen were similar between the two groups. Based on
Fig. 1. Fibrinogen, nitrated ﬁbrinogen, and D-dimer levels in VTE-negative and VTE-positive patients. (A) Plasma ﬁbrinogen levels were measured by two methods: ELISA,
which measures ﬁbrinogen antigen (VTE positive (þVTE), n 49, 5.5 mg/ml, 95% CI 4.9–6.2; VTE negative (VTE), n 194, 5.0 mg/ml, 95% CI 4.7–5.3), and Clauss assay,
which measures ﬁbrin clotting time (þVTE, n 44, 4.3 mg/ml, 95% CI 3.6–4.9; VTE, n 185, 4.0 mg/ml, 95% CI 3.8–4.2). Mean ﬁbrinogen levels for each assay were
compared by Mann–Whitney U test, Pwas nonsigniﬁcant for both comparisons. (B) Nitrated ﬁbrinogen levels measured by ELISA were elevated in þVTE (n 48) compared
to VTE (n 178) patients (62.7 nM, 95% CI 56.6–68.8 vs 54.2 nM, 95% CI 51.4–57.1). Nitrated ﬁbrinogen levels were compared by Mann–Whitney U test, *Po0.01.
(C) Spearman’s rank correlation analysis was used to evaluate the relationship between nitrated ﬁbrinogen and Clauss-measured ﬁbrinogen levels (n 207, r 0.31, 95% CI
0.18–0.40; Po0.0001). (D) D-dimer levels measured by Vidas D-dimer exclusion assay were higher in þVTE (n 42) versus VTE (n 157) patients (4.22 mg/ml, 95% CI
3.23–5.20 vs 1.42 mg/ml, 95% CI 1.20–1.63). D-dimer levels were compared by Mann–Whitney U test, **Po0.001. Data for (A), (B), and (D) are represented by box and
whisker plots in which the midline in the box is the median, the bottom and top of the box represent the 25th and 75th percentiles, respectively, and lower and upper bars
represent the 5th and 95th percentiles, respectively.
Fig. 2. Relationship between the odds ratio (OR) of acute VTE and nitrated
ﬁbrinogen levels. A cubic spline regression model of the odds ratio of acute VTE
as a function of nitrated ﬁbrinogen after adjustment for comorbidity, demo-
graphics, and risk factors is shown (n 226). Dotted lines represent the 95% CI.
Po0.005.
previous studies, the levels of nitrated ﬁbrinogen in VTE negative
patients are higher than would be expected in healthy nonsmok
ing controls [14,15]. This is probably due to the presence of
inﬂammatory and oxidative conditions in the VTE negative popu
lation, including CAD and smoking, which are associated with
increased plasma concentration of nitrated ﬁbrinogen [14 16].
Elevated levels of nitrated ﬁbrinogen in VTE, CAD, and smokers
suggest that inﬂammation and the production of nitric oxide
derived oxidants are present in thrombotic disorders as well as in
those at risk for the disease. Previous research on the functional
effects of nitration on ﬁbrinogen indicates that this modiﬁcation
contributes to a prothrombotic phenotype [14 16]. Thus, nitrated
ﬁbrinogen may serve as a comprehensive marker for activation of
inﬂammatory pathways during thrombosis. Increasing nitrated
ﬁbrinogen levels were positively associated with risk of VTE.
Compared with patients in the lowest quartile of nitrated ﬁbrino
gen, those in the highest quartile had a signiﬁcantly increased risk
of VTE. This relationship persisted after adjusting individually for
the risk factors that were elevated in the VTE positive group:
advanced age, active cancer, and recent surgery. However, this
risk was not maintained after adjusting for the combined factors.
The relatively small VTE positive patient group may account for
this difference, whereby adjustment reduces the positive group
sample size and eliminates statistical signiﬁcance. A larger study
would be needed to address this. The loss of signiﬁcance in our
multivariate regression analysis may also suggest that patients
with more than one of these risk factors also have elevated
nitrated ﬁbrinogen levels independent of VTE. Earlier work has
shown that nitrated proteins, including nitrated ﬁbrinogen, were
signiﬁcantly elevated in lung cancer patients [31]. Further studies
investigating nitrated ﬁbrinogen in advanced age, various cancer
types, and surgical patients would be necessary to evaluate these
effects. Advanced age, malignancy, and the postoperative state are
well accepted risk factors for VTE [1,32] and were more prevalent
among VTE positive than among VTE negative subjects in our
study. Other established risk factors were present in similar
proportions among the two groups, possibly owing to the rela
tively small size of our study and the small number of patients
harboring such risk factors.
In this study, nitrated ﬁbrinogen was found to be elevated in
the setting of acute VTE. It remains to be determined whether this
elevation reﬂects an underlying mediator of VTE pathology or is
merely a transient epiphenomenon of acute thrombosis. Studies
in which nitrated ﬁbrinogen levels are measured in patients at
risk for VTE, as well as in the weeks and months following an
event, are needed to address this question and may provide
valuable information regarding VTE recurrence.
Previous work has revealed that ﬁbrinogen is targeted for
oxidative modiﬁcations in vivo and in vitro [14 16,31,33 35].
Tyrosine nitration even in the presence of other oxidized amino
acids was shown to signiﬁcantly accelerate clot formation and
factor XIII cross linking [14,15,34,35]. Incorporation of nitrated
ﬁbrinogen molecules into ﬁbrin clots was documented by immu
noelectron microscopy and was found to alter clot architecture in
a dose dependent manner [14,15]. Changes in structure were
accompanied by changes in viscoelastic properties and a decrease
in dissolution by the ﬁbrinolytic systems [14,15]. Removal of the
nitrated ﬁbrinogen molecules restored the kinetics of ﬁbrin clot
formation and architecture [15]. These profound effects on ﬁbrin
clot structure were produced by a relatively small fraction of
ﬁbrinogen molecules modiﬁed by nitration. Based on previous
data and data reported herein, the yield of nitration represents
1 6% of ﬁbrinogen molecules [15]. Kinetic analysis of ﬁbrin
formation revealed that insertion of nitrated ﬁbrinogen molecules
accelerated lateral aggregation, an event that follows the initial
nucleation and the formation of half staggered, double stranded
protoﬁbrils [36 38]. This acceleration is probably due to
increased ‘‘B knob:b hole’’ interactions, which are facilitated by
the site speciﬁc nitration of two tyrosine residues near the b hole
of the b chain [15]. Overall, the concept that 1 nitrated molecule
per 100 normal ﬁbrinogen molecules can initiate the catalytic
increase in lateral aggregation is intriguing and consistent with
observations of other proteins that require nucleation events to
form protein ﬁbers [39]. These previous studies suggest that the
elevated levels of nitrated ﬁbrinogen in VTE positive patients
would result in an increase in the kinetics of clot formation and
subsequent changes in clot architecture. Additional studies are
necessary to address this hypothesis.
In addition to nitrated ﬁbrinogen, D dimer levels were sig
niﬁcantly elevated in VTE positive patients consistent with pre
vious studies [19,22 25]. Sensitivity and speciﬁcity for D dimer at
a 0.5 mg/ml cutoff in this patient population were 100% (95% CI
91.6 100) and 22.3% (95% CI 16.1 29.6), respectively, and are
similar to what has been previously reported for the Vidas
D dimer exclusion assay [19,25,40].
Fibrinogen is an independent risk factor and predictor of CAD
and associated morbidity and mortality [41,42]. However, its role
in VTE remains unclear. The Leiden Thrombophilia Study (LETS)
showed elevated ﬁbrinogen levels measured by Clauss assay in
DVT patients compared with healthy controls [43]. However, in
later investigations within LETS, increased risk of DVT with
increasing ﬁbrinogen levels was found only in patients 445 years
of age. In patients o45 years, ﬁbrinogen levels in the 95th
percentile did not confer increased risk of DVT [44]. Furthermore,
Table 2
Odds ratio of VTE by quartiles of nitrated ﬁbrinogen.
Quartile
1 2 3 4
Nitrated ﬁbrinogen o43.5 43.5–54.1 54.1–69.6 Z69.7
VTE 50 47 42 39
þVTE 7 9 14 18
Event rate 12.3% 16.1% 25.0% 31.6%
Unadjusted OR 1 1.37 (0.47–3.97) 2.38 (0.88–6.44) 3.30 (1.25–8.68)n
Adjusted OR (1) 1 1.30 (0.44–3.81) 2.22 (0.81–6.08) 3.25 (1.23–8.64)n
Adjusted OR (2) 1 1.37 (0.47–4.02) 2.42 (0.88–6.62) 2.84 (1.06–7.62)n
Adjusted OR (3) 1 1.26 (0.43–3.71) 2.23 (0.82–6.11) 2.84 (1.06–7.62)n
Adjusted OR (4) 1 1.21 (0.40–3.62) 2.17 (0.78–6.03) 2.55 (0.92–7.01)
Values listed as OR (95% CI). Models: 1, adjusted for age; 2, adjusted for cancer; 3, adjusted for surgery; 4, adjusted for age,
cancer, surgery. Odds ratios were compared by Fisher’s exact test.
n Po0.05.
in two separate studies in patients with suspected PE, the levels of
ﬁbrinogen were signiﬁcantly lower in patients diagnosed as
positive versus negative for the disease [45,46]. In this study,
ﬁbrinogen levels were similar between VTE positive and VTE
negative groups, and there were no differences in DVT versus PE
patients. Patient population or sample size may account for the
differences between this study and LETS, in which DVT patients
were compared to a large number of healthy age and sex
matched controls. Likewise, patient population may also explain
the dissimilarity between this study and the two previous studies
investigating ﬁbrinogen in PE [45,46].
Overall, ﬁbrinogen nitration in VTE patients certainly reﬂects
active inﬂammatory and oxidative states that could favor a
procoagulant environment resulting in ﬁbrin structures with
altered biochemical and biophysical properties. These alterations
in ﬁbrin clots may profoundly inﬂuence the pathology of VTE.
Acknowledgments
The work was supported by grants from the National Institutes
of Health (HL54926, HL103918, and ES013508, NIEHS Center of
Excellence in Environmental Toxicology to H.I.; HL098055 and
HL076491 to S.L.H.; and HL103931 to W.H.T.). M.R.M. is sup
ported by Hemostasis and Thrombosis Training Grant T32
HL07971. H.I. is the Gisela and Dennis Alter Research Professor
of Pediatric Neonatology at the Children’s Hospital of Philadelphia
Research Institute.
References
[1] Anderson Jr F. A.; Wheeler, H. B.; Goldberg, R. J.; Hosmer, D. W.; Patwardhan,
N. A.; Jovanovic, B.; Forcier, A.; Dalen, J. E. A population-based perspective of
the hospital incidence and case-fatality rates of deep vein thrombosis and
pulmonary embolism: the Worcester DVT study. Arch. Intern. Med.
151:933–938; 1991.
[2] Salomon, O.; Steinberg, D. M.; Zivelin, A.; Gitel, S.; Dardik, R.; Rosenberg, N.;
Berliner, S.; Inbal, A.; Many, A.; Lubetsky, A.; Varon, D.; Martinowitz, U.;
Seligsohn, U. Single and combined prothrombotic factors in patients with
idiopathic venous thromboembolism: prevalence and risk assessment. Arter-
ioscler. Thromb. Vasc. Biol 19:511–518; 1999.
[3] Pabinger, I.; Brucker, S.; Kyrle, P. A.; Schneider, B.; Korninger, H. C.; Niessner,
H.; Lechner, K. Hereditary deﬁciency of antithrombin III, protein C and
protein S: prevalence in patients with a history of venous thrombosis and
criteria for rational patient screening. Blood Coagul. Fibrinolysis 3:547–553;
1992.
[4] Heit, J. A.; Mohr, D. N.; Silverstein, M. D.; Petterson, T. M.; O’Fallon, W. M.;
Melton 3rd L. J. Predictors of recurrence after deep vein thrombosis and
pulmonary embolism: a population-based cohort study. Arch. Intern. Med.
160:761–768; 2000.
[5] Schulman, S.; Lindmarker, P.; Holmstrom, M.; Larfars, G.; Carlsson, A.; Nicol,
P.; Svensson, E.; Ljungberg, B.; Viering, S.; Nordlander, S.; Leijd, B.; Jahed, K.;
Hjorth, M.; Linder, O.; Beckman, M. Post-thrombotic syndrome, recurrence,
and death 10 years after the ﬁrst episode of venous thromboembolism
treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemostasis
4:734–742; 2006.
[6] U.S. Department of Health and Human Services Surgeon General’s call to action
to prevent deep vein thrombosis and pulmonary embolism. Washington, DC:
DHHS; 2008.
[7] Virchow, R. Thrombose und Embolie: Gefa¨ssentzu¨ndung und septische Infektion.
Frankfurt am Main: Von Meidinger & Sohn; 1856 pp. 219–732.
[8] Schaub, R. G.; Simmons, C. A.; Koets, M. H.; Romano 2nd P. J.; Stewart, G. J.
Early events in the formation of a venous thrombus following local trauma
and stasis. Lab. Invest 51:218–224; 1984.
[9] Myers Jr D.; Farris, D.; Hawley, A.; Wrobleski, S.; Chapman, A.; Stoolman, L.;
Knibbs, R.; Strieter, R.; Wakeﬁeld, T. Selectins inﬂuence thrombosis in a
mouse model of experimental deep venous thrombosis. J. Surg. Res
108:212–221; 2002.
[10] Geng, J. G.; MP, Bevilacqua; Moore, K. L.; McIntyre, T. M.; Prescott, S. M.; Kim,
J. M.; Bliss, G. A.; Zimmerman, G. A.; McEver, R. P. Rapid neutrophil adhesion
to activated endothelium mediated by GMP-140. Nature 343:757–760; 1990.
[11] Hrachovinova, I.; Cambien, B.; Hafezi-Moghadam, A.; Kappelmayer, J.;
Camphausen, R. T.; Widom, A.; Xia, L.; Kazazian Jr H. H.; Schaub, R. G.;
McEver, R. P.; Wagner, D. D. Interaction of P-selectin and PSGL-1 generates
microparticles that correct hemostasis in a mouse model of hemophilia A.
Nat. Med 9:1020–1025; 2003.
[12] Brennan, M. L.; Wu, W.; Fu, X.; Shen, Z.; Song, W.; Frost, H.; Vadseth, C.;
Narine, L.; Lenkiewicz, E.; Borchers, M. T.; Lusis, A. J.; Lee, J. J.; Lee, N. A.; Abu-
Soud, H. M.; Ischiropoulos, H.; Hazen, S. L. A tale of two controversies:
deﬁning both the role of peroxidases in nitrotyrosine formation in vivo
using eosinophil peroxidase and myeloperoxidase-deﬁcient mice, and the
nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem
277:17415–17427; 2002.
[13] Hazen, S. L.; Zhang, R.; Shen, Z.; Wu, W.; Podrez, E. A.; MacPherson, J. C.;
Schmitt, D.; Mitra, S. N.; Mukhopadhyay, C.; Chen, Y.; Cohen, P. A.; Hoff, H. F.;
Abu-Soud, H. M. Formation of nitric oxide-derived oxidants by myeloperox-
idase in monocytes: pathways for monocyte-mediated protein nitration and
lipid peroxidation in vivo. Circ. Res 85:950–958; 1999.
[14] Vadseth, C.; Souza, J. M.; Thomson, L.; Seagraves, A.; Nagaswami, C.; Scheiner,
T.; Torbet, J.; Vilaire, G.; Bennett, J. S.; Murciano, J. C.; Muzykantov, V.; Penn,
M. S.; Hazen, S. L.; Weisel, J. W.; Ischiropoulos, H. Pro-thrombotic state
induced by post-translational modiﬁcation of ﬁbrinogen by reactive nitrogen
species. J. Biol. Chem 279:8820–8826; 2004.
[15] Parastatidis, I.; Thomson, L.; Burke, A.; Chernysh, I.; Nagaswami, C.; Visser, J.;
Stamer, S.; Liebler, D. C.; Koliakos, G.; Heijnen, H. F.; Fitzgerald, G. A.; Weisel,
J. W.; Ischiropoulos, H. Fibrinogen b-chain tyrosine nitration is a prothrom-
botic risk factor. J. Biol. Chem. 283:33846–33853; 2008.
[16] Heffron, S. P.; Parastatidis, I.; Cuchel, M.; Wolfe, M. L.; Tadesse, M. G.; Mohler
3rd E. R.; Ischiropoulos, H.; Rader, D. J.; Reilly, M. P. Inﬂammation induces
ﬁbrinogen nitration in experimental human endotoxemia. Free Radic. Biol.
Med. 47:1140–1146; 2009.
[17] Heijnen, H. F.; van Donselaar, E.; Slot, J. W.; Fries, D. M.; Blachard-Fillion, B.;
Hodara, R.; Lightfoot, R.; Polydoro, M.; Spielberg, D.; Thomson, L.; Regan, E.
A.; Crapo, J.; Ischiropoulos, H. Subcellular localization of tyrosine-nitrated
proteins is dictated by reactive oxygen species generating enzymes and by
proximity to nitric oxide synthase. Free Radic. Biol. Med 40:1903–1913; 2006.
[18] Clauss, A. Gerinnungsphysiologische schnellmethode zur bestimmung des
ﬁbrinogens Acta Haematol 17: 237–246; 1957. /http://dx.doi.org/10.1159/
000205234S.
[19] de Moerloose, P.; Desmarais, S.; Bounameaux, H.; Reber, G.; Perrier, A.;
Dupuy, G.; Pittet, J. L. Contribution of a new, rapid, individual and quantita-
tive automated D-dimer ELISA to exclude pulmonary embolism. Thromb.
Haemostasis 75:11–13; 1996.
[20] Perrier, A.; Desmarais, S.; Miron, M. J.; de Moerloose, P.; Lepage, R.; Slosman,
D.; Didier, D.; Unger, P. F.; Patenaude, J. V.; Bounameaux, H. Non-invasive
diagnosis of venous thromboembolism in outpatients. Lancet 353:190–195;
1999.
[21] Kallner, A.; Egberg, N.; Yu, A.; Merzoug-Djilali, R.; Blomberg, I.; Jorneskog, G.;
Blomback, M. Are results of ﬁbrinogen measurements transferable? Clin.
Chem. Lab. Med 41:804–808; 2003.
[22] Bounameaux, H.; Ciraﬁci, P.; de Moerloose, P.; Schneider, P. A.; Slosman, D.;
Reber, G.; Unger, P. F. Measurement of D-dimer in plasma as diagnostic aid in
suspected pulmonary embolism. Lancet 337:196–200; 1991.
[23] Bozic, M.; Blinc, A.; Stegnar, M. D-dimer, other markers of haemostasis
activation and soluble adhesion molecules in patients with different clinical
probabilities of deep vein thrombosis. Thromb. Res 108:107–114; 2002.
[24] Declerck, P. J.; Mombaerts, P.; Holvoet, P.; De Mol, M.; Collen, D. Fibrinolytic
response and ﬁbrin fragment D-dimer levels in patients with deep vein
thrombosis. Thromb. Haemostasis 58:1024–1029; 1987.
[25] Di Nisio, M.; Squizzato, A.; Rutjes, A. W.; Buller, H. R.; Zwinderman, A. H.;
Bossuyt, P. M. Diagnostic accuracy of D-dimer test for exclusion of venous
thromboembolism: a systematic review. J. Thromb. Haemostasis 5:296–304;
2007.
[26] Nordenholz, K. E.; Mitchell, A. M.; Kline, J. A. Direct comparison of the
diagnostic accuracy of ﬁfty protein biological markers of pulmonary embo-
lism for use in the emergency department. Acad. Emerg. Med 15:795–799;
2008.
[27] Wakeﬁeld, T. W.; Strieter, R. M.; Wilke, C. A.; Kadell, A. M.; Wrobleski, S. K.;
Burdick, M. D.; Schmidt, R.; Kunkel, S. L.; Greenﬁeld, L. J. Venous thrombosis-
associated inﬂammation and attenuation with neutralizing antibodies to cyto-
kines and adhesion molecules. Arterioscler. Thromb. Vasc. Biol 15:258–268; 1995.
[28] Henke, P. K.; Varga, A.; De, S.; Deatrick, C. B.; Eliason, J.; Arenberg, D. A.;
Sukheepod, P.; Thanaporn, P.; Kunkel, S. L.; Upchurch Jr G. R.; Wakeﬁeld, T.
W. Deep vein thrombosis resolution is modulated by monocyte CXCR2-
mediated activity in a mouse model. Arterioscler. Thromb. Vasc. Biol
24:1130–1137; 2004.
[29] Lo, S. K.; Cheung, A.; Zheng, Q.; Silverstein, R. L. Induction of tissue factor on
monocytes by adhesion to endothelial cells. J. Immunol 154:4768–4777;
1995.
[30] Eiserich, J. P.; Hristova, M.; Cross, C. E.; Jones, A. D.; Freeman, B. A.; Halliwell,
B.; van der Vliet, A. Formation of nitric oxide-derived inﬂammatory oxidants
by myeloperoxidase in neutrophils. Nature 391:393–397; 1998.
[31] Pignatelli, B.; Li, C. Q.; Boffetta, P.; Chen, Q.; Ahrens, W.; Nyberg, F.; Mukeria,
A.; Bruske-Hohlfeld, I.; Fortes, C.; Constantinescu, V.; Ischiropoulos, H.;
Ohshima, H. Nitrated and oxidized plasma proteins in smokers and lung
cancer patients. Cancer Res 61:778–784; 2001.
[32] Heit, J. A.; Silverstein, M. D.; Mohr, D. N.; Petterson, T. M.; O’Fallon, W. M.;
Melton 3rd L. J. Risk factors for deep vein thrombosis and pulmonary
embolism: a population-based case–control study. Arch. Intern. Med
160:809–815; 2000.
[33] Parastatidis, I.; Thomson, L.; Fries, D. M.; Moore, R. E.; Tohyama, J.; Fu, X.;
Hazen, S. L.; Heijnen, H. F.; Dennehy, M. K.; Liebler, D. C.; Rader, D. J.;
Ischiropoulos, H. P. Increased protein nitration burden in the atherosclerotic
lesions and plasma of apolipoprotein A-I deﬁcient mice. Circ. Res
101:368–376; 2007.
[34] Inada, Y.; Hessel, B.; Blomback, B. Photooxidation of ﬁbrinogen in the
presence of methylene blue and its effect on polymerization. Biochim.
Biophys. Acta 532:161–170; 1978.
[35] Shacter, E.; Williams, J. A.; Levine, R. L. Oxidative modiﬁcation of ﬁbrinogen
inhibits thrombin-catalyzed clot formation. Free Radic. Biol. Med 18:815–821;
1995.
[36] Doolittle, R. F.; Pandi, L. Binding of synthetic B knobs to ﬁbrinogen changes
the character of ﬁbrin and inhibits its ability to activate tissue plasminogen
activator and its destruction by plasmin. Biochemistry 45:2657–2667; 2006.
[37] Geer, C. B.; Tripathy, A.; Schoenﬁsch, M. H.; Lord, S. T.; Gorkun, O. V. Role
of ‘B–b’ knob–hole interactions in ﬁbrin binding to adsorbed ﬁbrinogen.
J. Thromb. Haemostasis 5:2344–2351; 2007.
[38] Litvinov, R. I.; Gorkun, O. V.; Galanakis, D. K.; Yakovlev, S.; Medved, L.;
Shuman, H.; Weisel, J. W. Polymerization of ﬁbrin: direct observation and
quantiﬁcation of individual B:b knob–hole interactions. Blood 109:130–138;
2007.
[39] Hodara, R.; Norris, E. H.; Giasson, B. I.; Mishizen-Eberz, A. J.; Lynch, D. R.; Lee,
V. M.; Ischiropoulos, H. Functional consequences of a-synuclein tyrosine
nitration: diminished binding to lipid vesicles and increased ﬁbril formation.
J. Biol. Chem 279:47746–47753; 2004.
[40] Freyburger, G.; Trillaud, H.; Labrouche, S.; Gauthier, P.; Javorschi, S.; Bernard,
P.; Grenier, N. D-dimer strategy in thrombosis exclusion—a gold standard
study in 100 patients suspected of deep venous thrombosis or pulmonary
embolism: 8 DD methods compared. Thromb. Haemostasis 79:32–37; 1998.
[41] Benderly, M.; Graff, E.; Reicher-Reiss, H.; Behar, S.; Brunner, D.; Goldbourt, U.
Fibrinogen is a predictor of mortality in coronary heart disease patients: the
Bezaﬁbrate Infarction Prevention (BIP) Study Group. Arterioscler. Thromb.
Vasc. Biol 16:351–356; 1996.
[42] Folsom, A. R.; Wu, K. K.; Rosamond, W. D.; Sharrett, A. R.; Chambless, L. E.
Prospective study of hemostatic factors and incidence of coronary heart
disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation
96:1102–1108; 1997.
[43] Koster, T.; Rosendaal, F. R.; Reitsma, P. H.; van der Velden, P. A.; Briet, E.;
Vandenbroucke, J. P. Factor VII and ﬁbrinogen levels as risk factors for venous
thrombosis: a case–control study of plasma levels and DNA
polymorphisms—the Leiden Thrombophilia Study (LETS). Thromb. Haemos-
tasis 71:719–722; 1994.
[44] van Hylckama Vlieg, A.; Rosendaal, F. R. High levels of ﬁbrinogen are
associated with the risk of deep venous thrombosis mainly in the elderly.
J. Thromb. Haemostasis 1:2677–2678; 2003.
[45] Kucher, N.; Kohler, H. P.; Dornhofer, T.; Wallmann, D.; Lammle, B. Accuracy of
D-dimer/ﬁbrinogen ratio to predict pulmonary embolism: a prospective
diagnostic study. J. Thromb. Haemostasis 1:708–713; 2003.
[46] Kucher, N.; Schroeder, V.; Kohler, H. P. Role of blood coagulation factor XIII in
patients with acute pulmonary embolism: correlation of factor XIII antigen
levels with pulmonary occlusion rate, ﬁbrinogen, D-dimer, and clot ﬁrmness.
Thromb. Haemostasis 90:434–438; 2003.
Post-print standardized by MSL Academic Endeavors, the imprint of the Michael Schwartz Library at Cleveland State University, 
2017 
